Inspyr Therapeutics Inc (NSPX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
35
About the Report
About the Report
Summary
Inspyr Therapeutics Inc (Inspyr), formerly Genspera Inc is a biotechnology company that concentrates on the development of novel therapies for the treatment of cancer. The company is developing treatment in the areas including liver cancer, brain and prostate cancer. It is developing drug candidates for indications including HCC, GBM, PCa and RCC. Inspyr is developing drug candidate, which can be used for the treatment of hepatocellular carcinoma, glioblastoma and prostate cancer. The company's mipsagargin is in human clinical trials for patients with various different tumor types such as hepatocellular carcinoma, glioblastoma and prostate cancer. Inspyr is headquartered in Westlake Village, California, the US.
Inspyr Therapeutics Inc (NSPX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Inspyr Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Inspyr Therapeutics Raises USD0.3 Million in Financing 10
Lewis and Clark Pharma Raises USD 0.1 Million In Venture Financing 11
Private Equity 12
Inspyr Therapeutics to Raise up to USD100 Million in Private Equity Financing 12
Partnerships 13
Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 13
Inspyr Therapeutics Enters into Research Agreement with Winthrop-University 14
Inspyr Therapeutics Enters into Research Agreement with University of Virginia School of Medicine 15
Equity Offering 16
Inspyr Therapeutics Raises USD0.2 Million in Private Placement of Units 16
Inspyr Therapeutics Files Registration Statement for Public Offering of Shares 17
Inspyr Therapeutics Raises USD1 Million in Private Placement of Preferred Shares 18
GenSpera Raises USD2.5 Million in Private Placement of Series A Preferred Stock and Warrants 20
Inspyr Therapeutics Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 22
GenSpera Raises USD2.5 Million in Private Placement of Units 23
GenSpera Raises USD0.8 Million in Private Placement of Units 24
GenSpera Raises USD3.33 Million in Registered Public Offering of Units 25
GenSpera Completes Private Placement Of Units For USD 5 Million 27
GenSpera Completes Second Tranche Of Private Placement Of Shares For USD 1.9 Million 29
Debt Offering 30
Inspyr Therapeutics to Raise USD0.2 Million in Private Placement of Convertible Debentures Due 2018 30
Acquisition 31
Inspyr Therapeutics Acquires Lewis and Clark Pharma 31
Inspyr Therapeutics Inc-Key Competitors 32
Inspyr Therapeutics Inc-Key Employees 33
Inspyr Therapeutics Inc-Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Figure
List of Figures
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Inspyr Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Inspyr Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Inspyr Therapeutics Raises USD0.3 Million in Financing 10
Lewis and Clark Pharma Raises USD 0.1 Million In Venture Financing 11
Inspyr Therapeutics to Raise up to USD100 Million in Private Equity Financing 12
Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 13
Inspyr Therapeutics Enters into Research Agreement with Winthrop-University 14
Inspyr Therapeutics Enters into Research Agreement with University of Virginia School of Medicine 15
Inspyr Therapeutics Raises USD0.2 Million in Private Placement of Units 16
Inspyr Therapeutics Files Registration Statement for Public Offering of Shares 17
Inspyr Therapeutics Raises USD1 Million in Private Placement of Preferred Shares 18
GenSpera Raises USD2.5 Million in Private Placement of Series A Preferred Stock and Warrants 20
Inspyr Therapeutics Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 22
GenSpera Raises USD2.5 Million in Private Placement of Units 23
GenSpera Raises USD0.8 Million in Private Placement of Units 24
GenSpera Raises USD3.33 Million in Registered Public Offering of Units 25
GenSpera Completes Private Placement Of Units For USD 5 Million 27
GenSpera Completes Second Tranche Of Private Placement Of Shares For USD 1.9 Million 29
Inspyr Therapeutics to Raise USD0.2 Million in Private Placement of Convertible Debentures Due 2018 30
Inspyr Therapeutics Acquires Lewis and Clark Pharma 31
Inspyr Therapeutics Inc, Key Competitors 32
Inspyr Therapeutics Inc, Key Employees 33
Inspyr Therapeutics Inc, Subsidiaries 34
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.